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Covalent assembly of nanoparticles as a
peptidase-degradable platform for molecular MRI
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Ligand-conjugated microparticles of iron oxide (MPIO) have the potential to provide high
sensitivity contrast for molecular magnetic resonance imaging (MRI). However, the
accumulation and persistence of non-biodegradable micron-sized particles in liver and spleen
precludes their clinical use and limits the translational potential of MPIO-based contrast
agents. Here we show that ligand-targeted MPIO derived from multiple iron oxide
nanoparticles may be coupled covalently through peptide linkers that are designed to be
cleaved by intracellular macrophage proteases. The synthesized particles possess potential
characteristics for targeted MRI contrast agents, including high relaxivity, unappreciable
sedimentation, clearance from circulation and no overt toxicity. Importantly, we demonstrate
that these particles are rapidly degraded both in vitro and in vivo, and that the targeted probes
can be used for detection of inﬂammation in vivo using MRI. This approach provides
a platform for molecular MRI contrast agents that is potentially more suitable for translation
to humans.
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T
he high magnetization and low toxicity of superparamag-
netic iron oxide particles has led to their widespread use
in biomedical and biological applications1–3, including
MRI4,5, cancer therapy6, cell labelling7, biomolecule sensing8,9
and multimodal imaging10. These particles can be synthesized
across a range of diameters, of which the ultrasmall
superparamagnetic particles of iron oxide5 (USPIO; 20–50 nm
in diameter) have been clinically used the most. The long
circulation half-life of USPIO precludes rapid molecular imaging
of target-speciﬁc binding owing to high background levels11.
In contrast, microparticles of iron oxide (MPIO) have a short
half-life (o5min (ref. 12)) in the circulation and greater contrast-
to-noise per particle than USPIO owing to their higher iron
content (0.26 pg iron per particle versus 1.1 10 6 pg iron
per particle). Moreover, the increased surface area of MPIO
(ca. 2–12 mm2) compared with USPIO (ca. 0.005–0.03 mm2)
enables greater ligand valency, which can substantially increase
binding afﬁnities through multivalent effects13,14. In this context,
the strong correlation between target quantiﬁcation in tissue and
contrast volume on non-invasive MRI points strongly towards the
advantages of MPIOs15. The potential of MPIO for imaging
diagnostically useful endovascular cellular events, such as
inﬂammation and activated platelet adhesion, has already been
highlighted in a range of animal models of important human
disease, including multiple sclerosis16,17, thrombosis18,
atherosclerosis19, renal15 and cerebral ischaemia16,20, cerebral
malaria21 and brain metastases22. If such MPIO could be
synthesized in a biodegradable form, they have the potential to
provide superior capabilities for molecular imaging of disease in
humans (see Supplementary Note 1).
Although regulatory approval must of course be considered
on a case-by-case basis, we consider that translation to clinical
use requires a number of essential attributes: biocompatibility,
high iron content, controlled biodegradability, functionalizable
surface with multivalent capacity, appropriate shape to promote
multivalent binding to the planar endothelial surface, short
blood half-life, minimal non-speciﬁc accumulation and low
tendency to agglomerate. Here, we describe a microparticle
system designed through covalent assembly of multiple iron oxide
nanoparticles (NPs), which combines the advantages of the
micron-size iron particle range with biodegradability via the
endogenous clearance23–25 and degradation systems of the body
(Fig. 1, Supplementary Fig. 1). These microparticles are therefore
deserving of further research for their potentially enhanced utility
as in vivo imaging agents and potential clinical application as
iron-based molecular MRI contrast agents.
Results
mMPIO construction via iron oxide NP conjugation.
Biodegradable multimeric MPIO (mMPIO) were covalently
assembled from multiple colloidal iron oxide NPs of diameter
65 nm bearing an amine-functionalized dextran coat (Fig. 2).
These common precursor particles (Supplementary Figs 2 and
3 and Supplementary Tables 1 and 2) were then elaborated into
two complementary NP subtypes that could be readily coupled
together. In the ﬁrst subtype, carboxylate groups were created
from amino groups using succinic anhydride to form carboxy-
NPs26 (Supplementary Fig. 3). In the second, peptide sequences
were added to create peptido-NPs (Supplementary Fig. 3 and
Supplementary Table 3). These peptide sequences were carefully
designed to provide not only a suitable linker between monomer
particles but also a linker that would be sensitive to speciﬁc
intracellular degradative enzymes. Such proteases have previously
been shown to display strong potential in, for example, targeted
toxin release systems27,28 and are noted in differential regulation
in some disease states29. The cathepsin proteins are the primary
degradative enzymes in macrophages, which are the main
site of sequestration of iron oxide particles in the liver
and spleen on clearance from the circulation30–32. The
proteolytic activity of lysosomal cathepsin B (EC 3.4.22.1) and
L (EC 3.4.22.15) was tested against possible consensus peptide
sequences33–35. The most efﬁciently cleaved (Supplementary
Figs 4–8) yet plasma stable (Supplementary Figs 9 and 10)
peptide was chosen and incorporated. Stability of this
peptide under serum conditions was also tested (Supplementary
Figs 11–13); assays revealed degradation following clotting of
blood but stability upon treatment with EDTA (Supplementary
Fig. 13), suggesting susceptibility to metal-dependent proteases
induced in the clotting cascade (e.g., Factor IXa and XIa).
To stringently test the speciﬁcity of these chosen sequences we
created four homologues of the cathepsin L-speciﬁc peptide
Fmoc-Ahx-Ahx-FVRGAGE (Supplementary Fig. 4). In these
homologues, key residues were varied or scrambled, and D-amino
acids were used (including a ‘mirror-image’ peptide). When
examined in detail, through the kinetics of cleavage combined
with MS analysis (see Supplementary Figs 14–17 and
Supplementary Table 5), these revealed much lower cleavage
activity towards the scrambled and particularly the D-amino acid
peptide, as expected.
Using the carboxy-NP and peptido-NP monomers, larger
mMPIO were synthesized. This synthesis was performed using
robust amide-forming chemistry in MES buffer pH 6.0 via
N-hydroxysulfosuccinimide (sulfoNHS) ester36. The resulting
panel of mMPIO was characterized and optimized for key
parameters, including size, yield and reactivity (Fig. 3a and
Supplementary Table 4). Combined electron microscopy, trans-
mission electron microscopy (TEM), atomic force microscopy
(AFM), zeta potential and dynamic light scattering (DLS)
measurements conﬁrmed construction and the anticipated
morphology and characteristics of our designed larger,
multimeric particles (Fig. 3b and Supplementary Fig. 18 and
Supplementary Tables 4 and 6). Composition and dextran
content were further conﬁrmed by chemical and elemental
analyses. Importantly, by varying the reaction ratio of the two
monomer types it was possible to change both the particle size
and the nature of the surface reactive functional groups of the
resulting mMPIO (Fig. 3a and Supplementary Table 4), which in
turn would ensure that a broad range of targeting ligands could
be conjugated. This approach, therefore, allowed us to readily
create mMPIO bearing either an excess of amine (mMPIO-NH2)
or those bearing an excess of carboxylic acid (mMPIO-COOH).
mMPIOs show low sedimentation and high MRI relaxivities.
We have previously shown that microparticles of 0.5–1mm
diameter combine favourable characteristics of high contrast
effect and rapid blood phase clearance rate that are well suited
to in vivo targeting studies16, by delivering efﬁcient particle
binding to the site of interest and low background signal at
the time of MRI. At the same time, the MPIO are still
much smaller than erythrocytes and not prone to microvascular
plugging. mMPIO within this size range were efﬁciently
and reliably constructed through modulation of the starting
ratios of the two monomers (Fig. 3a). These mMPIO exhibited
physicochemical advantages over equivalent monomeric
iron-dextran MPIO (B0.7 mm diameter; see Supplementary
Methods for synthesis). In particular, the mMPIO showed
very little tendency to precipitate, with sedimentation
rates markedly lower than correspondingly sized monomeric
particles and commercially available polystyrene-coated particles
(o1, 51 and 86% of sedimentation at 24 h, respectively;
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Supplementary Figs 19 and 20); such effects potentially increase
the translational potential of the mMPIOs and may be due
to crosslinking or surface charge changes (although they
are consistent with many different surface potential
levels; Supplementary Fig. 3). Moreover, the mMPIO displayed
storage stability at 4 C for more than 6 months (Fig. 3c).
They also exhibited signiﬁcantly higher T2 relaxivities
(194.5±4.5mM 1 s 1 at 4.7 T and 196.5±4.9mM 1 s 1 at
7 T; Fig. 3d and Supplementary Fig. 21 and Supplementary
Table 7) than commercially available polystyrene-coated
particles (58.5±2.2 and 59.5±1.2mM 1 s 1 at 4.7 and
7 T, respectively; Supplementary Table 7) that have previously16
demonstrated good contrast in vivo, potentially due to
previously noted magnetic relaxation switch phenomena9.
Inflammatory disease present(i)
(ii)
(iii)
Inflammatory disease absent
Liver clearance
Figure 1 | Molecular basis of mMPIO as a targeted MRI contrast agent. Intravenously injected targeted mMPIO bind to their target on the diseased
endothelial surface (i), but do not bind to healthy endothelium (ii). The unbound mMPIO are rapidly cleared from blood. Thus, negligible background
contrast effects are evident with mMPIO shortly after injection. mMPIO are efﬁciently taken up by macrophages (iii), and after internalization and fusion to
lysosomes the internal peptide linkers are degraded. mMPIO are represented as brown sphere conglomerates, iron oxide nanoparticles are represented as
brown spheres, targeting agents are represented in dark blue and endothelial surface disease markers are shown in green.
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Figure 2 | Schematic representation of the synthesis of mMPIO. Grey spheres represent amine-functionalized dextran-coated iron oxide nanoparticles,
blue spheres represent peptido-NPs and brown spheres represent carboxy-NPs. Conditions: (i) peptide 3, N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide
hydrochloride (EDC) N-hydroxysuccinimide (NHS), 2-(N-morpholino)ethanesulfonic acid (MES) buffer (0.1M pH6.0)/dimethylsulfoxide (DMSO) 1:1;
(ii) piperidine/ N,N-dimethylformamide (DMF)/DMSO (2:3:5); (iii) succinic anhydride, sodium bicarbonate buffer (0.1M pH 8.3)/DMSO 1:1;
(iv) EDC, sulfoNHS, MES buffer (0.1M pH 6.0); (v) when an excess of carboxy-NPs are used an mMPIO with excess surface carboxylic acid functions is
formed; when an excess of peptido-NPs is employed the mMPIO surface contains excess amine functions (not shown).
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mMPIO are biodegraded in vitro and in cellulo. Next,
the biodegradability of the mMPIO was evaluated in vitro.
Consistent with their molecular design, incubation of mMPIO
with both cathepsins B and L efﬁciently degraded the peptide
linker yielding the monomeric NPs from which they were
built (Fig. 4a). Having demonstrated the biodegradable nature
of the linker with respect to the appropriate enzymes, cellular
uptake and intracellular degradation of the mMPIO were
evaluated. Both amino-terminated mMPIO (mMPIO-NH2)
and carboxylic acid-terminated mMPIO (mMPIO-COOH)
(entries 3 and 7 from Fig. 3a, respectively) were labelled with the
ﬂuorophore AlexaFluor 488 cadaverine. These ﬂuorescently
labelled mMPIO were incubated with cultured macrophages.
Confocal time-course experiments showed a consistent and
clear reduction in the number of intracellular mMPIO over
12 h (Fig. 4b, Supplementary Figs 22 and 23 and Supplementary
Movie 1). Further experiments (Supplementary Figs 24 and 25)
showed that punctuate ﬂuorescence in the intracellular com-
partment faded over time. After 72 h, the ﬂuorescence was
homogeneously distributed and no large particles were detectable,
suggesting complete degradation. By comparison, the equivalent
large (733 nm) amino-terminated monomeric MPIO remained
intact after 48 h, with only slight degradation after 72 h
(Supplementary Fig. 26), suggesting a considerably slower rate of
degradation compared with the mMPIO. Cellular uptake of the
mMPIO was conﬁrmed and subcellular distribution of the
degradation products was also analyzed in macrophage cell line
(RAW 264.7) using TEM (see Supplementary Fig. 27) over 72 h.
Upon internalization into the distinctive cell morphology of the
cells, mMPIO were clearly surrounded by visible membrane
structures, suggesting anticipated formation of endolysosomal
compartments within which the structure of the mMPIO
degraded. This conﬁrmed the uptake into phagosomes of
high-intensity material containing iron and then its loss over
time. In contrast, commercially available monomeric MPIO beads
remained intact (with high iron content) throughout. We also
constructed mMPIOs linked by peptides containing D-amino
acids in the same sequence used for the degradable mMPIOs;
consistent with the resistance shown by D-amino acid-containing
peptides to cathepsins, these ‘D’-mMPIO were not degraded
(Supplementary Figs 28–32). These experiments further
supported both the efﬁcacy and the molecular mechanistic basis
of the designed degradable ‘L’-mMPIO system.
mMPIOs are not non-speciﬁally retained and clear rapidly.
Having conﬁrmed in vitro degradation of the mMPIO, the in vivo
biodistribution and clearance of the mMPIO were evaluated
histologically (Fig. 4c,d and Supplementary Figs 33 and 34).
Both mMPIO-NH2 and the equivalent size, amino-terminated,
monomeric MPIO were injected intravenously into naı¨ve mice.
Primary uptake of both the mMPIO and monomeric MPIO was
evident in the liver 1 h after injection, and in both cases the
particles were almost entirely cleared from this site by 7 days.
Low-level mMPIO retention was also observed in the intestine
and lung at 1 h, although the level of particle staining was
low compared with that observed in the liver (0.001 and
0.044, respectively, versus 0.208% area stained) and, again, was
negligible by 7 days. Similar low levels of monomeric MPIO
retention were found in the intestine. In striking contrast,
substantial monomeric MPIO retention was evident in the
lungs, which was lower but still evident 14 days post-injection
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Figure 3 | Physicochemical characterization of mMPIO. (a) Size and yield of mMPIO as a function of carboxy-NP/peptido-NP ratio. [a]Ratio between
carboxy-NPs and peptido-NPs (w/w). [b]Determined by dynamic light scattering (DLS). (b) Microscopic characterization of mMPIO by TEM (top three
images showing different representative examples; scale bars left-to-right 100, 100 and 50 nm), atomic force microscopy (bottom left, scale bar 50 nm)
and HRTEM (bottom middle and right; bottom right is the inset magniﬁcation from bottom middle; scale bars 50 and 5 nm). (c) DLS size distribution
graph of B700nm mMPIO just after synthesis (red line) and after storage for 6 months (blue line). (d) T2-weighted images of the phantoms
(iron concentration¼0.224mM) at echo times 9.7ms (left) and 16.3ms (right).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14254
4 NATURE COMMUNICATIONS | 8:14254 | DOI: 10.1038/ncomms14254 | www.nature.com/naturecommunications
(ca. 1% tissue area). The lung is known to play an important
role in removing blood-borne foreign bodies via adherent
phagocytes and endothelial cells, and particles cleared in this way
are passed through the endothelium to accumulate in macro-
phages in the alveolar interstitium37. Thus, it might be expected
that MPIO would also be cleared from the circulation by this
pathway. Unlike the MPIO, however, the mMPIO were not
cleared to any appreciable extent via the lungs (cf. 1 h data;
Fig. 4c,d and Supplementary Fig. 34), reﬂecting their different
physicochemical properties. Very low and constant levels of iron
staining were evident in the white pulp of the spleen in both
mMPIO- and MPIO-injected animals (0.1–0.2% tissue area),
while the very high intrinsic iron levels in the red pulp of the
spleen precluded quantitation of the small increases arising from
mMPIO/MPIO accumulation. No appreciable retention of the
mMPIO or monomeric MPIO was found in heart, brain or
kidney (o0.0005% of tissue area; Supplementary Fig. 33).
Importantly, for our goal of creating a ﬂexible particle system,
chemical surface functionality did not alter in vivo distribution;
no appreciable differences were seen in animals injected
with mMPIO-COOH compared with those injected with
mMPIO-NH2.
To assess whether labelling of the mMPIO with targeting
antibodies altered the clearance proﬁle and to obtain
formal toxicological data, preclincial studies were conducted
(Sequani; see Supplementary Methods) in which mice
were injected with mMPIO conjugated to a humanized anti-
human-vascular cell adhesion molecule (VCAM)-1 antibody
(ahuVCAM) with cross-reactivity to mouse (ahuVCAM-
mMPIO). All values for clinical observations (body weight, organ
weights, macroscopic histology) were within normal ranges, and
no blood chemistry (Supplementary Tables 9 and 10), haemato-
logical (Supplementary Tables 11 and 12) or histological ﬁndings
(Supplementary Fig. 35) were of toxicological signiﬁcance. In
accord with our ﬁndings above, a very low level of diffuse iron
staining was found in the liver 2 days after administration of
ahuVCAM-mMPIO in 5/6 mice, which was no longer evident by
14 days post-ahuVCAM-mMPIO injection (Supplementary
Fig. 35). In-house quantitative analyses conﬁrmed the absence
of particulate iron deposits (i.e., undegraded mMPIO) at both 2
and 14 days post-ahuVCAM-mMPIO injection, indicating
degradation within the ﬁrst 48 h period. No ahuVCAM-mMPIO
retention was evident in any other tissue, or in control animals, at
either time point. Thus, the biodistribution proﬁle of the mMPIO
remained the same when conjugated to a targeting antibody.
Since VCAM-1 is not highly expressed on vascular endothelium
under normal conditions, accumulation in tissue beds expressing
VCAM-1 other than the brain was not examined, as this would
have required different disease models. No evidence of infarction
or inﬂammation was found in any of the organs studied in any of
the above studies, up to 14 days post-mMPIO injection.
Antibody-targeted mMPIOs allow molecular imaging. Having
established biodistribution proﬁles, the utility of this platform
to create targeted mMPIO as tools for molecular imaging
was tested. The diversity of functional groups in the mMPIO,
which is a consequence of their multimeric assembly, also allowed
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Figure 4 | In vitro and in vivo degradation studies. (a) DLS analysis of particle size distribution of mMPIO after addition of cathepsin L. Particle size was
analysed at different time points 0 h (red line), 1 h (blue line), 4 h (light green), 8 h (purple) and 24h (dark green). Experiments were performed in
triplicate. (b) Time-course montage of particle degradation by the murine macrophage cell line RAW264.7 obtained by live cell confocal imaging.
Visible particles are indicated by black arrows. Experiments were performed in triplicate. Scale bar 10 mm. (c) Graph to show distribution of ca. 700nm
mMPIO and MPIO in different organs 1 h and 7 days after intravenous injection (n¼ 3 per group). Data are mean±s.d. for three ﬁelds per organ.
*Po0.05 based on one-way ANOVA on a tissue-wise basis followed by Newman–Keuls post-hoc tests. (d) Images of immunohistochemical sections taken
from different organs 1 h and 7 days after intravenous injection of either mMPIO or MPIO. Sections have been stained with Prussian Blue to identify iron and
counterstained with Nuclear Fast Red. Magniﬁcation is 400, scale bar¼ 50mm.
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ready orthogonal labelling such that different moieties could
be incorporated via different functional groups (Supplementary
Fig. 36). In this way, mMPIO were created that contained
both multiple ﬂuorescent labels (AF488) in the inner core of the
particle and high levels of surface, targeting moieties. Particles
were synthesized bearing either an anti-VCAM-1 antibody
(aVCAM) or a corresponding IgG control antibody (aVCAM-
AF488-mMPIO and IgG-AF488-mMPIO, respectively). Both
targeted particles exhibited similarly high surface antibody den-
sity (Supplementary Fig. 37). As expected, aVCAM-AF488-
mMPIO, but not IgG-AF488-mMPIO, showed high binding
capacity towards activated endothelial cells in vitro
(Supplementary Fig. 38).
Finally, the potential of the aVCAM-AF488-mMPIO for
in vivo molecular MRI was evaluated in a mouse model of
cerebral inﬂammation. Mice were injected intracerebrally
with interleukin-1b (IL-1b) in the left striatum to induce
endothelial activation and VCAM-1 expression16. In animals
subsequently injected intravenously with aVCAM-AF488-
mMPIO, a marked contrast effect was evident in the
T2*-weighted images, manifest as focal hypointensities in the
IL-1b-injected hemisphere (Fig. 5a,c, Supplementary Fig. 39a
and Supplementary Movie 2). Notably, the contrast effect
was unilateral with no non-speciﬁc mMPIO-induced
hypointensities in the non-injected hemisphere. Negligible
contrast effects arising from mMPIO retention were present in
any of the controls: (i) naı¨ve mouse injected intravenously
with aVCAM-AF488-mMPIO; (ii) mouse injected intracerebrally
with saline and intravenously with aVCAM-AF488-mMPIO;
and (iii) mouse injected intracerebrally with IL-1b and
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Figure 5 | In vivo VCAM-1-targeting experiments. (a,b) Selected T2*-weighted images from 3D data sets obtained from mice injected intrastriatally with
IL-1b 3 h before intravenous injection of either (a) aVCAM-AF488-mMPIO or (b) control non-targeted IgG-AF488-mMPIO. Focal hypointense areas
(black) in the left hemisphere reﬂect the speciﬁc aVCAM-AF488-mMPIO retention on acutely activated vascular endothelium (a), with negligible contrast
effects evident in either the contralateral control hemisphere or in the animal injected with IgG-AF488-mMPIO (b). Box indicates the injected hemisphere.
(c,d) 3D reconstructions of the mMPIO-induced hypointensities (coloured in red) from mice injected with either aVCAM-AF488-mMPIO
(c) or IgG-AF488-mMPIO (d) shown both as a stacked plot (left) and within the mouse brain frame of reference (right). Negligible contrast effects
are evident in the animal injected with IgG-AF488-mMPIO. (e) Graph to show volumes of hypointensities in aVCAM-AF488-mMPIO-injected mice
(black circles; n¼ 3) and controls (black square, IL-1bþ IgG-AF488-mMPIO; black triangle, salineþ IgG-AF488-mMPIO; black diamond,
naiveþ aVCAM-AF488-mMPIO). Data are shown as speciﬁc contrast (left–right difference) for each animal; note negligible speciﬁc contrast is apparent in
the control mice. Each data point represents an individual mouse; since this was a proof-of-principle experiment to demonstrate in vivo contrast effects,
statistical analysis was not performed. (f–i) Immunohistochemical and immunoﬂuoresence images of brain sections taken from IL-1b-injected mice.
f (i, ii) Immunohistochemical sections showing VCAM-1 expression (brown) co-localized with aVCAM-AF488-mMPIO (Prussian Blue staining).
Epiﬂuorescence (g (i)) and confocal (g (ii)) images further demonstrate adherence of aVCAM-AF488-mMPIO (green) to VCAM-1-positive (red) vessels.
Nuclei are stained with DAPI (blue). Additional alkaline phosphatase staining enabled co-localization of aVCAM-AF488-mMPIO (green) with
VCAM-1 (blue) and vessels (laminin—red) to be conﬁrmed using both epiﬂuorescence (h (i)) and confocal (h (ii) and i (i, ii)) microscopy. Arrows indicate
aVCAM-AF488-mMPIO. Scale bars¼ 10 mm (f (i,ii); h (ii); i (i,ii)) and 5 mm (g (i,ii); h (i)).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14254
6 NATURE COMMUNICATIONS | 8:14254 | DOI: 10.1038/ncomms14254 | www.nature.com/naturecommunications
intravenously with the non-targeted IgG-AF488-mMPIO
(Fig. 5b,d, Supplementary Fig. 39b and Supplementary
Movie 3). Quantitative analyses of the volumes of hypointensity
induced by aVCAM-AF488-mMPIO binding yielded
substantially greater volumes in the IL-1b-injected animals
than in any of the control animals (Fig. 5e). Subsequent
T1-weighted images acquired after intravenous administration
of the passive contrast agent gadolinium-DTPA revealed no
areas of contrast enhancement in any animal, verifying that the
blood–brain barrier was intact. Taken together, these data
indicate speciﬁc binding of aVCAM-AF488-mMPIO to acutely
activated endothelium in the absence of blood–brain barrier
breakdown.
Following the in vivo MRI experiments, co-localization of
VCAM-1 expression and aVCAM-AF488-mMPIO binding was
veriﬁed both immunohistochemically and by immunoﬂuores-
cence (Fig. 5f–i). Immunohistochemical analysis demonstrated
upregulation of VCAM-1 in the IL-1b-injected, but not the
contralateral, hemisphere. Subsequent Prussian Blue detection of
iron revealed the presence of bound aVCAM-AF488-mMPIO in
VCAM-1-positive vessels (Fig. 5f). Both epiﬂuorescence and
confocal microscopy of the brain sections further conﬁrmed
successful co-localization of the aVCAM-AF488-mMPIO with
both VCAM-1 and laminin, indicating association of the targeted
mMPIO with VCAM-1-positive vessels (Fig. 5g–i).
Discussion
We have demonstrated here some potential advantages conferred
by the use of covalent linkages for the synthesis of mMPIO that
include control of size and enhanced stability. These are both
prerequisites for clinical use of the agent that are not provided by,
for example, current methodologies based on non-covalent
linkages8,9.
We have demonstrated here these mMPIOs as intravascular
agents. In the system we propose here, molecular targeting is
determined by a surface-displayed binding agent on the particle
and an appropriate ‘biomarker’ binding partner on the cell
surface. We should add the clear caveat that we have only tested a
single targeting antibody type (anti-VCAM); other important
target sites also exist (e.g., interstitial space or poorly vascularized
tumour cells) for imaging on which they might also be tested in
the future. However, at such sites targeted agents may lose their
molecular selectivity since they can also accumulate passively.
The choice of a cathepsin-cleavable peptide as the linker
ensured rapid degradation of the mMPIO once sequestered by
macrophages, primarily within the liver following clearance from
circulation30,31, while particles that associate with their target
remain unaltered and functional. Rapid sedimentation, slow
degradation and mechanical retention in organs23,24, such as the
lung, make the corresponding monomeric MPIO particles
unsuitable for use in man. In contrast, the mMPIO appear to
possess properties that are useful for clinical application of
molecular imaging, such as high relaxivity (see Supplementary
Table 8), unappreciable sedimentation rate, rapid degradation, no
overt toxicity and fast clearance from circulation. Owing to these
mechanistic differences, unlike toxic particles where dose would
be rapidly limiting, excesses of mMPIO can advantageously be
used. In this way, percentage binding can be even tuned
accordingly, since any excess that does not bind is non-toxic,
cleared rapidly and degraded. This therefore provides both a vital
mechanistic and potential translational advantage. Thus, while
key additional translational hurdles will need to be considered in
even greater detail for future development and regulatory
approval (i.e., stability, reproducibility, dispersity), we believe
that these proof-of-principle experiments with mMPIO might
provide a promising platform for the clinical use of molecular
MRI contrast agents.
Methods
General considerations. All animal experiments were authorized by the
UK Home Ofﬁce. Chemical abbreviations and details of the equipment employed
are given in Supplementary Methods.
Synthesis of dextran covered NPs. About 5mmol of FeCl3  6H2O and 9, 10 or
12 g of dextran average mol. wt. 9,000–11,000 (SigmaAldrich, cat. Nr. D9260,
lot Nr. 1331472 or 1382459) or 7.3 g of Dextran 10 Pharmaceutical Quality
(Pharmacosmos, batch Nr. HX4271) were dissolved in 20ml of water and
deoxygenated thoroughly by repeated cycles of vacuum assisted by sonication and
argon ﬂushing. After the ﬁrst deoxygenation cycle, 3mmol of FeCl2  4H2O in 5ml
of water was added and the solution was deoxygenated by the above procedure
(four times). While being stirred with an overhead stirrer at 600 r.p.m., NH4OH
(4ml, 25%) was added at a rate of 168ml h 1. The reaction was heated to 80 C
and then stirred at this temperature for 1 h. The solution was cooled and placed in
a SpectraPor membrane (MWCO 100,000) leaving some space for volume increase.
The solution was dialysed against 5 l of water for 21 h with water changes at times
1, 2 and 4 h. Iron content was measured spectrophotometrically at 410 nm after
acid dissolution (6M HCl (aq)) and oxidation (3% hydrogen peroxide solution) for
1 h (ref. 38), and adjusted to a ﬁnal concentration of 10mg Fe per ml using a
Vivaspin centrifugal unit (MWCO 30.000). An aliquot (10 ml) was diluted with
700 ml of phosphate-buffered saline (PBS) and particle size was determined by DLS.
A sample (5mg of iron) was freeze dried and elemental analysis was determined
(Supplementary Methods and Supplementary Table 1).
Synthesis of amino-terminated NPs. Twenty millilitres of dextran covered
NPs (10mgml 1) were placed into a 250-ml round ﬂask equipped with
a 30 16mm oval stirrer bar. While the solution was stirred at 500 r.p.m.,
36.7ml of NaOH 5M was added at a rate of 168ml h 1. After that, 13.3ml of
epichlorohydrin (20ml in case of Phamacosmos HX4271 dextran, results
‘k–l’ Supplementary Table 1) was added at a rate of 94ml h 1. The mixture was
stirred at 1,000 r.p.m. for 7 h and then 20ml of NH4OH (25%) was added at a rate
of 168ml h 1. The mixture was stirred at 1,000 r.p.m. for 14 h and then was placed
in a SpectraPor 2 or 100 kDa cutoff membrane leaving some space for volume
increase. The solution was then dialysed against 5 l of water for 21 h with water
changes at times 1, 2 and 4 h and the dialysate concentrated on a Vivaspin
15 unit (MCWO 30.000) to 15mg Fe per ml. A sample (5mg of iron) was freeze
dried and elemental analysis was determined (Supplementary Methods and
Supplementary Table 2).
Synthesis of carboxylic acid terminated NPs. Succinic anhydride in dimethyl
sulfoxide (DMSO) (4ml, 15mgml 1) was added to a solution of amino-NPs
(8ml, 10mg Fe per ml) in sodium bicarbonate buffer 100mM pH 8.3. Note: The
reaction is exothermic and a nitrogen-ﬁlled balloon with a syringe was placed on
the tube. The mixture was shaken for 3 h, then 4ml of succinic anhydride in DMSO
(15mgml 1) was added and the mixture shaken for a further 3 h. The sample
was dialyzed in a 10,000Da dialysis membrane against 5 l of water for 21 h with
water changes at times 1, 2 and 4 h and was concentrated in a Vivaspin 20 unit
(MCWO 30.000) to 15mg Fe per ml.
Peptide synthesis. SPPS peptide synthesis was performed under standard
Fmoc-conditions using HBTU/HOBt as an activator and DIPEA as a base catalyst.
Deprotection and couplings were performed under microwave irradiation
employing a single coupling protocol except for the ﬁrst residue, which
was introduced by double coupling. Peptide cleavage was performed using
TFA/TIS/H2O 95:2.5:2.5 (10ml per g resin). The solvent was partially evaporated
and the peptide was precipitated by addition of a cold mixture of diethylether/
hexane 1:1, centrifuged and washed again with the same mixture. The peptide was
homogenized, dried under high vacuum for 3 h, re-dissolved in water/acetonitrile/
DMSO/TFA 70:15:5:0.1 and puriﬁed by preparative RP chromatography. This
product was dissolved in 2% DMSO in water and analysed by high-performance
liquid chromatography (HPLC). For structure of peptides, see Supplementary
Fig. 4. Peptides were characterized by HPLC, high-resolution mass spectrometry
and tandem mass spectrometry (MS/MS) (Supplementary Figs 40–47 and
Supplementary Tables 13–17). The proteolytic activity of the cathepsins on the
peptides was analyzed by HPLC (Supplementary Methods).
Synthesis of peptide covered NPs (peptido-NPs). A solution of EDC in
water (0.84ml, 38mgml 1) was added to a solution of peptide 3 (200mg) and
NHS (24mg) in DMSO (3.7ml). This solution was incubated for 5min at r.t. and
then added to a solution of 20mg of amino-NPs in 3.3ml of MES buffer 0.1M
pH 6.0. The solution was shaken for 3 h at room temperature (r.t.), and then split
into two 50ml centrifuge tubes. Particles were precipitated by addition of 45ml of
acetonitrile, centrifuged for 20min at 3250g and the supernatant was carefully
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discarded taking care not to disturb the precipitate. The precipitate was
re-suspended in 5ml of DMSO, an aliquot (100 ml) was taken and Fmoc analysis
was performed (Supplementary Methods). The rest of the sample was precipitated
again by addition of 45ml of acetonitrile and centrifuged as before. Samples were
re-suspended in 5ml of DMSO and 5ml of 40% piperidine in DMF was added.
The samples were shaken for 30min after which the particles were precipitated by
addition of 45ml of 1,4-dioxane. Samples were re-suspended in 5ml of DMSO and
the deprotection step was repeated. Precipitate was re-suspended in water, dialyzed
in a 10.000 MWCO dialysis membrane against 5 l of water for 21 h with
water changes at times 1, 2 and 4 h and was concentrated in a Vivaspin 6 unit
(MCWO 30.000) to 15mg Fe per ml (Supplementary Table 3). An essentially
similar method was used for the synthesis of D-peptido-NPs containing D-amino
acids in the peptide.
Synthesis of amino-terminated mMPIOs (mMPIO-NH2). A solution of
carboxy-NPs (25.5 ml, 11.2mg Fe per ml, 0.285mg Fe) in MES buffer 0.1M
pH 6.0 was activated by sequential addition of sulfoNHS (2 ml, 1.5 eq. respect to
the N content of its amino-NPs precursor; see Supplementary Table 2) and of
EDC (1ml, 1.2 eq. respect to the N content of its amino-NPs precursor; see
Supplementary Table 2) in MES buffer 0.1M pH 6.0. The resulting solution was
shaken and incubated at r.t. for 5min and added to a solution of peptido-NPs
(171 ml, 10mgml 1, 1.71mg Fe) in MES buffer 0.1M pH 6.0. The reaction was
shaken at 55 C for 24 h at 1,400 r.p.m.. Once the reaction had ﬁnished the
sample was diluted and puriﬁed by dialysis and either by magnetic pelleting
(Supplementary Methods) or by sucrose gradient (Supplementary Methods).
An aliquot (2ml) was redispersed in 700 ml of PBS and size was measured by
DLS (Supplementary Table 4). An essentially similar method was used for the
synthesis of the D-amino-acid-mMPIOs from D-peptido-NPs.
Synthesis of carboxy-terminated mMPIOs (mMPIO-COOH). A solution
of carboxy-NPs (122 ml, 15.3mg Fe per ml, 1.71mg Fe) in MES buffer 0.1M
pH 6.0 was activated by sequential addition of sulfoNHS (15ml, 1.5 eq. respect
to the N content of its amino-NPs precursor; see Supplementary Table 2) and of
EDC (10 ml, 1.2 eq. respect to the N content of its amino-NPs precursor;
Supplementary Table 2) in MES buffer 0.1M pH 6.0. The resulting solution was
shaken and incubated at r.t. for 5min and added to a solution of peptido-NPs
(22.8 ml, 12.5mg per ml, 0.285mg Fe) in MES buffer 0.1M pH 6.0. The reaction
was shaken at 55 C for 24 h at 1,400 r.p.m.. Once the reaction had ﬁnished the
sample was diluted and puriﬁed by dialysis and either by magnetic pelleting
(Supplementary Methods) or by sucrose gradient (Supplementary Methods).
An aliquot (2ml) was redispersed in 700 ml of PBS and particle size measured
(Supplementary Table 4).
Sedimentation of particles. A solution of mMPIO or 733 nm MPIO
(for synthesis see Supplementary Methods) (0.11mg Fe per ml) was placed,
after vortexing and sonication, in a quartz cuvette equipped with PTFE stopper.
Absorption was measured at l¼ 500 nm for 24 h at 5min time intervals.
Relaxivity of compounds. Phantoms were prepared by addition of 0.75ml
of an agarose solution (12%) to 0.75ml of serial dilutions of the contrast agent
in a Nalgene Cryoware vial. Samples were centrifuged at 1,000g for 5min to
eliminate air bubbles. MRI experiments were performed on Magnex 4.7 or
7.0 T superconductive magnet driven by Varian DirectDrive spectrometer
(Magnex Scientiﬁc and Varian Inc.; subsidiaries of Agilent Technologies, Santa
Clara, CA, USA). A spin-echo sequence was used to acquire T2 and T1 maps. Single
slice images were acquired with a matrix size of 128 128 pixels in all cases,
corresponding to voxel dimensions of 0.4 0.4 5.0mm. T2 maps were generated
from a series of spin echo images (repetition time (TR)¼ 3.0 s) in which the echo
time (TE) was logarithmically distributed in 10 steps from 9.7 to 100ms. The total
experimental time was ca. 1 h. T1 maps were generated from a series of inversion
recovery spin echo images (TR¼ 10.0 s; TE¼ 9.7ms) in which the inversion
recovery time was logarithmically distributed in 10 steps from 10ms to 6.0 s.
The total experimental time was ca. 3.5 h. The relaxation maps were calculated
using a standard mono-exponential ﬁt employing a least-squares procedure.
In vitro degradation of mMPIO by cathepsin L. Cathepsin L (0.88 mg) in 98ml of
citrate buffer 0.1M pH 5.0 containing 1mM EDTA was activated by addition of
DTT (2 ml, 100mM in water). After 15min at r.t., this pre-activated solution was
added to 0.4mg of mMPIO in 400 ml citrate buffer pH 5.0. The solution was
incubated at 37 C and at selected time points 100ml of solution was taken and
1 ml of the potent cysteine protease inhibitor E-64 (Sigma-Aldrich, UK) solution
1mM in DMSO was added. After 1 h at 4 C the sample was diluted to 700ml and
particle size measured.
In vitro macrophage uptake and degradation experiments. The synthesis of
ﬂuorescent-labelled mMPIO (with both L- and D-amino acid peptide linkers)
and monomeric MPIO was performed as described in Supplementary Methods.
RAW264.7 murine macrophage cells (ATCC) were grown in DMEM supple-
mented with 10% FBS until ca. 50% conﬂuent. Cells were incubated with 1 mg of
multimeric particles (per 35mm culture dish) for 30min at 37 C. Culture medium
was replaced with fresh, pre-warmed complete Dulbecco’s Modiﬁed Eagle’s
medium, and live cell experiments performed at 37 C using a Zeiss LSM510 laser
scanning confocal equipped with a microscope incubator (CO2¼ 5%). Images were
collected using a 63X 1.4NA objective, with the 488-nm laser line of an argon laser
used for ﬂuorescence and transmitted light imaging. Twelve hours time courses
were run; imaging interval, 2min. Further experiments were performed in freshly
isolated murine macrophages (Supplementary Methods) and the subcellular
degradation process was monitored by TEM (Supplementary Methods).
In vivo mMPIO uptake and clearance experiments. Adult male NMRI mice
(30–40 g) were anaesthetized and injected intravenously with 4mg Fe per kg body
weight of (i) mMPIO-NH2 or (ii) equivalent sized amine-terminated monomeric
MPIO. Animals were transcardially perfused with saline followed by 4% paraf-
ormaldehyde at either 1 h or 7 days (n¼ 3 per group) after microparticle injection.
Two additional animals were injected with the same dose (4mg Fe per kg) of
mMPIO-COOH and perfused 7 days post-injection. A further group of animals
injected with the monomeric MPIO were perfused 14 days post-injection (n¼ 3).
All in vivo experiments were approved by the UK Home Ofﬁce.
Tissue samples from brain, heart, lung, kidney, liver, spleen and intestine were
post-ﬁxed for 7 days and parafﬁn wax embedded. Ten micrometre sections were
dried overnight, de-waxed and stained for iron using Perls’ Prussian Blue stain
with a Nuclear Fast Red counterstain. For each tissue, three ﬁelds of view
per animal at  400 magniﬁcation were analysed using a semiautomated
thresholding method (ImageJ) to determine the percentage area of iron staining.
Thresholding criteria, based on hue, saturation and luminosity values speciﬁc
to the microparticles were constant for each tissue. Differences between groups
were assessed using ANOVA followed by post-hoc pairwise t-tests with
a Welch’s correction for unequal variances where appropriate; group sizes were
based on previous clearance experiments with commercial MPIO. Mice were
assigned randomly to each group, and all analysis was performed blind to the
sample groups.
Subsequently, a single dose extended acute toxicology study was commissioned
from the Commercial Research Organization Sequani Ltd (full details in
Supplementary Methods). The following assessments were made: body weight,
organ weights, macroscopic pathology, haematology and blood chemistry. In
addition, microscopic analysis, including assessment of iron deposition, was
conducted on brain (at three levels), heart, kidney, liver, lung and spleen tissue.
Subsequent in-house quantitative analysis of Perls’ staining was performed as
described above. Group sizes were determined by Sequani Ltd based on previous
toxicology work, mice were assigned randomly to each group and analysis was
performed blind to sample group.
Synthesis of ﬂuorescently labelled, targeted mMPIOs. A solution of
AlexaFluor 488 SDP ester (2mg per ml, 250 ml) in DMSO was added to a solution
of mMPIO-COOH (5ml, 1mg Fe per ml) in sodium bicarbonate buffer 0.1M
pH 8.3. The reaction was shaken for 24 h. Particles were collected using a Dynal
magnet (Invitrogen, UK) and washed. Particles were resuspended in 900 ml of
MES buffer 0.1M pH 6.0. SulfoNHS (2 ml, 1M) in water and EDC (3.5 ml, 0.1M) in
water were sequentially added to 180 ml of the AF488-mMPIO solution. The
resultant solution was stirred for 15min at room temperature and then 400 ml of
rat anti-mouse VCAM-1 (clone M/K2) or rat IgG2a isotype control antibody
(clone KLH/G2a-1-1) (0.5mgml 1) followed by 400ml of sodium bicarbonate
buffer 0.1M pH 8.3 was added. The sample was shaken for 24 h. Particles were
collected using a magnet (Invitrogen) washed and resuspended in 200 ml of
PBS buffer. The antibody loading was determined on multimeric particles from
ﬂuorescence intensity using Qiﬁkit calibration beads (Dako, UK) according
to the manufacturer’s protocol, but substituting the provided ﬂuorescently
conjugated antibody with AlexaFluor594-conjugated rabbit anti-rat IgG (Hþ L)
(Invitrogen; Cat. Nr. A-21211). mMPIO containing 5 mg iron were diluted in 200ml
of 1 PBS/0.1% Tween-20. AlexaFluor594-conjugated goat anti-mouse IgG
(Hþ L) (Invitrogen; Cat. Nr. A-11005) (8 mg) was added and incubated at 4 C for
1 h. The particles were pelleted on a Dynal magnetic separator (Invitrogen) and
washed three times with 1 PBS/0.1% Tween 20. Flow cytometry experiments
were performed on a BD LSRII ﬂow cytometer and the data analysed using
Flow Jo (Tree Star Inc., OR, USA).
In vitro antibody-mMPIO binding experiments. Murine endothelial
(sEnd.1, PMID: 2736622) cells, cultured in 35mm dishes cultured in 35mm dishes
(Corning, USA), were stimulated with recombinant mouse tumor necrosis factor-a
for 8 h, ﬁxed with 4% formaldehyde for 10min at room temperature, washed with
PBS and stored at 4 C. aVCAM-AF488-mMPIO (1.625 mg Fe per ml), IgG-AF488-
mMPIO (1.625 mg Fe per ml) or PBS was added to cells and these were placed
on a bench-top rocker for 5min at r.t. prior to thorough washing with PBS. Particle
binding events were visualized using a  40, 0.6 NA objective ﬁtted to an Olympus
IX-71 microscope.
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In vivo anti-VCAM-1-targeted experiments. Adult male NMRI mice
(30–40 g or 10–12 weeks, n¼ 3) were anaesthetized with 2.0–2.5% isoﬂurane
in 70% N2O:30% O2 and stereotaxically microinjected in the left striatum
(co-ordinates from Bregma: anterior 0.5mm, lateral 2mm, depth 2.5mm) with
20 ng of recombinant mouse IL-1b in 1 ml low endotoxin saline (n¼ 3).
After 3.1±0.1 h, mice were re-anaesthetized and injected via a tail vein with
aVCAM-AF488-mMPIO (4mg Fe per kg). Three control mice were studied:
(i) naı¨ve mouse injected intravenously with aVCAM-AF488-mMPIO as above;
(ii) mouse injected intracerebrally with vehicle (1 ml saline) and intravenously
with aVCAM-AF488-mMPIO after 3.2 h; and (iii) mouse injected intracerebrally
with 20 ng IL-1b in 1 ml saline and intravenously with the non-targeted
IgG-AF488-mMPIO after 3.0 h. Following mMPIO injection, animals were
positioned in a quadrature birdcage coil. During MRI, anaesthesia was maintained
with 1.5–1.8% isoﬂurane, and electrocardiogram was monitored and body
temperature maintained at B37 C. All in vivo experiments were approved by the
UK Home Ofﬁce.
Magnetic resonance imaging. A T2*-weighted three-dimensional gradient echo
data set was acquired: ﬂip angle¼ 27; TR¼ 65ms; TE¼ 7.5ms; ﬁeld of view
(FOV)¼ 11.2mm 22.5mm 22.5mm; matrix size, 96 192 256; number of
averages¼ 2; total acquisition time B40min. Mid-point of acquisition was
1.6±0.4 h after microparticle injection. Data were zero-ﬁlled to 128 256 256;
ﬁnal isotropic resolution B88mm. Brains were masked, thresholded and MPIO
binding quantiﬁed. Spin-echo T1-weighted images (TR¼ 500ms; TE¼ 20ms;
FOV 25mm 25mm; matrix size, 128 128) were acquired pre- and 5min
post-Gd-DTPA injection (Omniscan; GE Healthcare, UK; 30 ml, i.v.). Each
T2*-weighted data set was converted into tiff images, manually masked to exclude
extracerebral structures and converted to 8-bit greyscale in Adobe Photoshop
(Adobe Systems Incorporated, UK). The images were thresholded at a consistent
level in the grey channel, such that any pixels of signal intensity43 s.d. below the
mean intensity of normal brain were set to zero (black) and all others were set
to 1 (white), see Supplementary Fig. 39. The absolute level of thresholding varied
between data sets according to variations in signal-to-noise. Signals arising from
ventricles or sinuses were excluded by comparison to a naı¨ve animal imaged with
no contrast agent, in which these structures appear hypointense naturally.
The masked and thresholded images were subsequently imported into ImagePro
(Media Cybernetic, UK) and stacked into a single sequence. mMPIO binding,
deﬁned as all pixels with signal levels of zero, was quantiﬁed in 160 consecutive
brain slices for each animal. Analysis was performed blind to the origin of
the dataset. Segmented images were reconstructed using the three-dimensional
Constructor plug-in to visualize the spatial distribution of binding, with
low-signal areas assigned to the red channel and the anatomical image to the green
channel. Voxel volumes were summed and expressed as raw volumes in microlitres
with no surface rendering or smoothing effects. Since these were proof-of-principle
experiments, to demonstrate the in vivo contrast effects of the mMPIO, only
a sufﬁcient number of animals were studied to demonstrate that these effects were
reproducible and statistical analysis was not performed.
Immunohistochemistry and immunoﬂuorescence. Following MRI, animals were
transcardially perfused and the brains post-ﬁxed, cryoprotected, embedded and
frozen in isopentane. Expression of VCAM-1 and co-localization with mMPIO
was veriﬁed both by immunoﬂuorescence microscopy and immunohistochemically
(rat anti-mouse VCAM-1 (clone M/K2)) using avidin–biotin complex
ampliﬁcation22. To verify co-localization of the mMPIO with VCAM-1
expression, Prussian-blue staining to detect iron oxide was performed. Following
completion of VCAM-1 immunohistochemistry, some slides were incubated with
20% hydrochloric acid and 10% potassium hexacyanoferrate(II) trihydrate for
20min at 37 C. After washing with PBS, the slices were then counterstained with
cresyl violet.
Microscopy. Images were acquired using either an inverted epiﬂuorescence
microscope (DM IRB; Leica Microsystems, Wetzlar, Germany) or an inverted
confocal microscope (LSM-710; Carl Zeiss Microimaging, Jena, Germany) and
analysed using Image J and Zen (Carl Zeiss) software.
The LSM-710 confocal microscope was equipped with PC-Apochromat
 63 1.2NA oil immersion objective lens. Detection ranges were set to eliminate
crosstalk between ﬂuorophores: 409–485 nm for DAPI, 494–553 nm for AlexaFluor
488 and 564–712 nm for Cy3. The set of dichroics MBS 488/561 and MBS-405 were
used. The 32 PMT array of the confocal was used to record lambda images that
were subsequently unmixed with the Zen software using individually recorded
spectra, thus removing inherent autoﬂuorescent signal from the tissue.
Data availability. The particle sizing, MRI, microscope images and HPLC data
that support the ﬁndings of this study are available in Oxford University ORA data
system with the identiﬁer https://doi.org/10.5287/bodleian:qaY9QE2kN. Other
data that support the ﬁndings of this study are available from the corresponding
authors upon request.
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